CHU Dual-Energy Ablation in Ventricular Arrhythmia

Inclusion Criteria: * Patient age ≥ 18 years and ≤ 75 years； * Clinically diagnosed with tachyarrhythmia, specifically idiopathic ventricular arrhythmia； * Recurrent disease with obvious symptoms prior to enrollment; * Failure to respond to or intolerance of at least one antiarrhythmic drug; * Fully understand the treatment plan, voluntarily sign the informed consent form, and agree to undergo the examinations, procedures and follow-up as required by the protocol. Exclusion Criteria: * Left ventricular ejection fraction (LVEF) ≤ 40% * History of ventricular flutter or ventricular fibrillation * Diagnosis of long QT syndrome or arrhythmogenic cardiomyopathy * Presence of structural heart disease or organic heart disease, including hypertrophic cardiomyopathy, dilated cardiomyopathy, ischemic cardiomyopathy, rheumatic heart disease, and congenital heart disease * Previous atrial septal repair or atrial myxoma * Carrying an active implantable device in the body (e.g., cardiac pacemaker, ICD, etc.) * NYHA functional class Ⅲ-Ⅳ * Patients with documented cerebrovascular disease within the past 6 months (including cerebral hemorrhage, stroke, transient ischemic attack) * Patients with cardiovascular events within the past 3 months (including acute myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting, prosthetic valve replacement or repair, atrial or ventricular incision) * Patients with acute or severe systemic infection * Patients with severe hepatic or renal disease, malignant tumor, or end-stage disease, who, in the investigator's judgment, may interfere with the treatment, evaluation, or compliance of this trial * Patients with significant bleeding tendency, hypercoagulable state, or severe hematological disorders * Patients who have participated in or are currently participating in other clinical trials within 3 months prior to enrollment * Patients with other conditions deemed inappropriate for participation in this trial by the investigator.